Email this article Sunitinib - standard second-line therapy of metastatic gastro-intestinal stromal tumors (review of literature and case reports)
- Authors: Meshcheryakov A.A.1, Filonenko D.A1, Petukhova S.V2
-
Affiliations:
- N.N. Blokhin Russian Lancer Research Center
- “Central Clinical Hospital with Outpatient Health Center” of the Business Administration for the President of the Russian Federation
- Issue: Vol 20, No 2 (2015)
- Pages: 48-53
- Section: Articles
- URL: https://ogarev-online.ru/1028-9984/article/view/40162
- DOI: https://doi.org/10.17816/onco40162
- ID: 40162
Cite item
Full Text
Abstract
Treatment of gastrointestinal stromal tumors actively developed. Standard second-line treatment of disseminated gastrointestinal stromal tumors is sunitinib (Sutent). Its effectiveness is proven in a randomized, double-blind, multicenter, international phase III trial NCT 00075218. This review summarizes recent data on the epidemiology and diagnosis of the disease, a common approach to the treatment of early and advanced disease, the results of the registration study of sunitinib phase III clinical recommendations to reduce the frequency and severity of adverse events. Particular attention is paid to the factors that are key to achieving the maximum clinical efficacy of sunitinib, namely, prevention and treatment of adverse events, optimizing the dosage regimen and duration of treatment. The article illustrates own clinical observations that demonstrate the efficacy of sunitinib as second-line therapy of disseminated gastrointestinal stromal tumors.
Full Text
##article.viewOnOriginalSite##About the authors
Andrey A. Meshcheryakov
N.N. Blokhin Russian Lancer Research Center
Email: a_meshcheryakov@mail.ru
MD, PhD 115478, Moscow, Russian Federation
D. A Filonenko
N.N. Blokhin Russian Lancer Research Center115478, Moscow, Russian Federation
S. V Petukhova
“Central Clinical Hospital with Outpatient Health Center” of the Business Administration for the President of the Russian Federation121359, Moscow, Russian Federation
References
- Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B. et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 2005; 103(4): 821-9.
- Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014; 25 (Suppl. 3): iii21-iii26.
- Kawanowa K., Sakuma Y., Sakurai S., Hishima T., Iwasaki Y., Saito K. et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006; 37(12): 1527-35. Epub 2006 Sep 25.
- Tryggvason G., Gislason H.G., Magnйsson M.K., Jonasson J.G. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int. J. Cancer. 2005; 117(2): 289-93.
- Miettinen M., Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006; 130: 1466-78.
- Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosisat different sites. Semin. Diagn. Pathol. 2006; 23: 70-83.
- Gold J.S., Gonen M., Gutierrez A. et al. Development and validation of a prognostic nomogram f or recurrence-free survival after complete surgical resection of localized primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009; 10: 1045-52.
- Joensuu H., Vehtari A., Riihimaki J. et al. Risk of recurrence of gastrointestinal stromal tumor after surgery: an nalysis of pooled population-based cohorts. Lancet Oncol. 2012; 13: 265-74.
- Joensuu H., Eriksson M., Sundby Hall K. et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. J. A. M. A. 2012; 307: 1265-72.
- Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329-38.
- Demetri G.D., Garrett C.R., Schoffski P., Shah M.H., Verweij J., Leyvraz S. et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin. Cancer Res. 2012; 18(11): 3170-9. doi: 10.1158/1078-0432.CCR-11-3005.
- Castellano D., Ravaud A., Schmidinger M. et al. Therapy management with sunitinib in patients with metastatic renal call carcinoma: key concepts and the impact of clinical biomarkers. Cancer Treat. Rev. 2013; 39: 230-40.
- Мещеряков А.А., Цымжитова Н.Ц., Филоненко Д.А., Медведева Б.М. Оценка эффективности таргетной терапии на примере клинического случая стромальной опухоли желудочно-кишечного тракта. Саркомы костей, мягких тканей и опухоли кожи. 2013; 2: 38-42.
- NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 2. 2014.
- Практические рекомендации по лекарственному лечению больных гастроинтестинальными стромальными опухолями (GIST). Практические рекомендации RUSSCO. Версия 2014 г.
Supplementary files
